Core Insights - Oncternal Therapeutics has completed enrollment and initiated dosing for the sixth dose cohort of its Phase 1/2 study of ONCT-534, targeting metastatic castration-resistant prostate cancer (mCRPC) patients who are relapsed or refractory to approved androgen receptor pathway inhibitors [1][2] - The sixth cohort is receiving ONCT-534 at a dose of 1200 mg orally once daily, following a decision by the Safety Review Committee based on data from the previous 600 mg cohort [1][2] - Initial safety and efficacy data based on prostate-specific antigen (PSA) levels from this study is expected in Q3 2024, including results from the 1200 mg dose cohort [1][2] Company Overview - Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies for cancers with critical unmet medical needs, particularly in hematological malignancies and prostate cancer [6] - ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with preclinical activity against both unmutated androgen receptors and various forms of androgen receptor aberrations, aimed at treating mCRPC patients resistant to existing therapies [6] - The company is also developing ONCT-808, an investigational CAR T cell therapy targeting ROR1, which has shown activity in preclinical models against multiple cancers [6]
Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer